Ehud Zigmond

Cirrhosis Risk in Sarcoidosis Without Documented Hepatic Involvement—A Large Nationwide Population‐Based Cohort Study

Uria Shani, Yana Davidov, Ehud Zigmond, Tomer Ben‐Ami et autres

BACKGROUND & AIMS: Given the likely underestimation of hepatic sarcoidosis, the aims were to evaluate long-term cirrhosis risk in patients with sarcoidosis without documented hepatic involvement at baseline and to assess the impact of multi-organ disease and immunomodulatory therapies on cirrhosis risk. …

il (code pays fourni par la source)

Prognostic Performance of Liver Stiffness Measurements in Primary Sclerosing Cholangitis: The Prospective FICUS cohort

Olivier Chazouillères, Jonathan Bellet, Christoph Schramm, Palak Trivedi et autres

BACKGROUND & AIMS: Predicting outcomes of primary sclerosing cholangitis (PSC) by reliable and simple tools is an unmet need. Retrospective studies have suggested that liver stiffness measurement (LSM) by vibration-controlled transient elastography (FibroScan, Echosens) can predict outcomes. We aimed to validate the …

fr, de, gb, fi, it, es, us, nl, dk, il, ca (code pays fourni par la source)

Long-lasting extracellular matrix modifications reshape intestinal stem cell fate and promote chronic inflammation

Idan Adir, Carmel Sochen, Sivan Gelb, Aviya Habshush Menachem et autres

il, dk, fi (code pays fourni par la source)

Serum Anti-Saccharomyces cerevisiae Antibody Is Associated with Disease Severity in Patients with Primary Sclerosing Cholangitis

Niv Zmora, Lian Bannon, Roie Tzadok, Noy Nachmias et autres

Introduction: Primary sclerosing cholangitis (PSC) is a chronic liver disease accompanying inflammatory bowel disease (IBD). Anti-Saccharomyces cerevisiae antibody (ASCA) is a serological marker associated with aggressive IBD phenotype. Data on the association between ASCA and liver outcomes remain elusive. We aimed to …

il (code pays fourni par la source)

Tu2024 VOLIXIBAT LEADS TO IMPROVEMENTS IN FATIGUE AND SLEEP FOR ADULTS WITH PRIMARY BILIARY CHOLANGITIS: DATA FROM VANTAGE

Mitchell L. Shiffman, Debra Weinstein, Victor Ankoma-Sey, Nimer Assy et autres

Tu2023 EXPLORING THE ROLE OF VOLIXIBAT, AN ILEAL BILE ACID TRANSPORTER INHIBITOR, IN THE REGULATION OF IL-31 AND SERUM BILE ACIDS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: PRELIMINARY RESULTS FROM THE VANTAGE TRIAL

Mitchell L. Shiffman, Alan Bonder, Debra Weinstein, Victor Ankoma-Sey et autres

Tu2023 EXPLORING THE ROLE OF VOLIXIBAT, AN ILEAL BILE ACID TRANSPORTER INHIBITOR, IN THE REGULATION OF IL-31 AND SERUM BILE ACIDS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: PRELIMINARY RESULTS FROM THE VANTAGE TRIAL

Mitchell L. Shiffman, Alan Bonder, Debra Weinstein, Victor Ankoma-Sey et autres

Tu2024 VOLIXIBAT LEADS TO IMPROVEMENTS IN FATIGUE AND SLEEP FOR ADULTS WITH PRIMARY BILIARY CHOLANGITIS: DATA FROM VANTAGE

Mitchell L. Shiffman, Debra Weinstein, Victor Ankoma-Sey, Nimer Assy et autres

SAT-320 Impact of metabolic dysfunction-associated steatotic liver disease on treatment response, clinical outcomes and prognosis in primary biliary cholangitis: findings from a large multicenter longitudinal GLOBAL PBC registry

Ellina Lytvyak, Yu JunWong, Bettina E. Hansen, Laurent Lam et autres

LBO-006 Efficacy and safety of volixibat, an IBAT inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: results of the VISTAS trial

Cynthia Levy, Gideon M. Hirschfield, Mitchell Shiffman, Muyiwa Awoniyi et autres

SAT-254 Seladelpar effect on lipids and muscle safety with concomitant statin use in patients with primary biliary cholangitis: interim results from the open-label ASSURE study with up to 4 years of treatment

Christopher L. Bowlus, Yusuf Yilmaz, Ehud Zigmond, Victor Vargas Blasco et autres

147 - VOLIXIBAT FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS: AN ADAPTIVE, RANDOMIZED, PLACEBOCONTROLLED PHASE 2B TRIAL (VANTAGE): 28-WEEK INTERIM RESULTS

Michael A. Heneghan, Mitchell L. Shiffman, Debra Weinstein, Victor Ankoma-Sey et autres